Crohn's Disease: KOL Insights on Treatment Practices and Unmet Needs

  • ID: 1780989
  • Drug Pipelines
  • 150 Pages
  • Sociable Pharma
1 of 5

FEATURED COMPANIES

  • Alaven
  • AstraZeneca
  • Centocor
  • Genzyme
  • Ovamed
  • Salix
  • MORE
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future and also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

Highlights:

- Identifies the latest treatment trends in Crohn's disease, including the growing importance of “top-down” treatment strategies for moderate-to-severe Crohn's disease
- Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
- Analyzes current treatment practices covering seven major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, antibiotics, probiotics and nutritional therapy
- Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the emerging treatment objective of complete mucosal healing
- Assesses the impact of the SONIC trial
- Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include improving anti-TNF response duration and managing long-term immunosuppression.

Research highlights

Understand key treatment trends
- The growing importance of “top-down” treatment strategies for moderate-to-severe Crohn's disease
- Shifting treatment objectives towards complete mucosal healing

Identify unmet needs
- Managing patients on long-term immunosuppression
- Optimizing thiopurine dosing
- Improving anti-TNF response duration
- Timing the initiation of anti-TNF therapy

4 treatment maps & 53 treatment settings
- A visual guide to the treatment of Crohn's disease, based on extensive primary and secondary research

Analysis of current US/EU treatment practices involving 7 drug classes
- Corticosteroids, 5-ASAs, antibiotics, probiotics, nutritional therapy, immunomodulators, anti-TNF therapies

16 unmet needs identified
- Based on KOL research and meetings at ECCO 2011
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alaven
  • AstraZeneca
  • Centocor
  • Genzyme
  • Ovamed
  • Salix
  • MORE
Executive Summary



Scope of analysis & methodology

Current treatment practice
– Corticosteroids
– Aminosalicylates
– Immunomodulators
– Anti-TNF therapies
– Antibiotics
– Nutritional therapies



Unmet needs



Crohn's Disease Treatment Map
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AstraZeneca
- Prometheus
- Forest
- UCB Pharma
- Ferring
- Shire
- Warner Chilcott
- Salix
- Alaven
- Axcan
- Pfizer
- Almirall
- GSK
- Centocor
- Merck
- TOA Probiotics
- Teva
- Genzyme
- Cellerix
- Ovamed
- Asphelia
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll